A trial led by the Duke Clinical Research Institute, Durham, has investigated the long-term safety and efficacy of supplementing heart failure patients with iron.
Ferric carboxymaltose is an iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell for a controlled delivery of iron to target tissues and is administered intravenously.
The HEART-FID trial aimed to assess the long-term safety and efficacy of ferric carboxymaltose in heart failure patients with iron deficiency. Unlike some previous studies, this trial did not find a significant reduction in hospitalizations for heart failure with ferric carboxymaltose. The AFFIRM-AHF trial is mentioned as one of the previous trials. It suggested a reduction in recurrent hospitalizations for heart failure but did not show a significant decrease in cardiovascular mortality with ferric carboxymaltose compared to placebo.
The IRONMAN trial, which assessed a different intravenous iron formulation , is also discussed. It showed findings similar to those in the AFFIRM-AHF trial, with a reduction in recurrent hospitalization forThe authors point out that these previous trials occurred during the COVID-19 pandemic, which may have influenced hospitalization rates and outcomes.Robert J.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Opening all arteries best when heart attack strikes in old age: StudyAfter a heart attack, elderly adults have better odds for improved health and survival if all major heart vessels are cleared, not just the one that caused the heart attack.
Læs mere »
British Heart Foundation publishes worrying ultra-processed foods studyThe British Heart Foundation has published a worrying study linking ultra-processed foods to high blood pressure, heart disease, heart attacks and…
Læs mere »
New drug targeting genetic variant in Parkinson's disease found to be ineffective in clinical trialAn experimental drug targeting a genetic variant linked to Parkinson's disease had no effect on patients, according to the results of a new clinical trial published in The Lancet Neurology.
Læs mere »
First randomized trial of traditional Chinese medicine for heart failure shows benefitThe traditional Chinese medicine qiliqiangxin reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Læs mere »
Trial of ferric carboxymaltose in heart failure does not meet primary endpointFerric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalizations and exercise function in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Læs mere »
DICTATE-AHF trial fails to meet primary endpoint with dapagliflozin in acute heart failureEarly initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalized patients with acute decompensated heart failure (ADHF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Læs mere »